Navigation Links
Halt Medical Presents Strong Results of International Fibroid Studies at National Institutes of Health Global Congress

BETHESDA, Md., Dec. 20, 2010 /PRNewswire/ -- Women suffering from uterine fibroids, a debilitating condition that affects more than seven million women in the U.S., may soon have reason for hope.  Halt Medical, a biomedical company based in the San Francisco Bay Area, is developing a minimally invasive procedure for treating the condition. The company recently presented their findings from studies in Latin America at the NIH Global Fibroid Congress.  

"Uterine fibroids are the leading cause of women's surgeries worldwide," says Russ DeLonzor, President and Chief Operating Officer of Halt.  "Currently women must choose between suffering with their symptoms or sacrificing their uterus." The symptoms can be severe, ranging from acute pelvic pain, urinary incontinence, and painful intercourse, to excessive menstrual bleeding.

"Hysterectomy surgeries can be highly traumatic for women," says DeLonzor. "It's not only an emotional decision, but also a painful one, with a typical six-week recovery time. Halt Medical was formed with a single goal in mind," adds DeLonzor, "to give women suffering with the awful symptoms caused by fibroids an alternative to losing their uterus."

The Halt Fibroid System is a precise, minimally invasive outpatient procedure that allows women to return to normal activities in just 3 – 4 days.  A slender probe is inserted into the fibroid under ultrasound guidance. Once in position, the system delivers a specified amount of energy to the fibroid.  The heat generated in the process destroys the fibroid, relieving the symptoms while sparing the uterus.     

"We commend the NIH for sponsoring this forum," DeLonzor says. "Uterine fibroids are a significant public health issue, and we are honored to share the results of our Latin American Studies."  

The results of Halt's international studies have led to recent approvals for treating uterine fibroids in Canada and the European Union.  The Halt System may be used for general surgical use in the US, however it is currently cleared by the FDA only for investigational use for treating symptomatic fibroids.  

Information about the Halt Fibroid Study and a list of clinical sites in the US may be found at, study number NCT00874029.

SOURCE Halt Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
2. Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
3. ICON Medical Imaging Launches New Service to Boost Reliability of Cardiology Studies
4. Informed Medical Communications Highlights Opportunity in Revised PhRMA Code
5. Concentric Medical(R) Announces Co-Marketing Agreement With InTouch Health(R) to Advance Acute Ischemic Stroke Care
6. BioMS Medical Announces Second Quarter 2008 Results
7. ATS Medical to Participate at the Fourth Annual Noble Financial Equity Conference
8. Mentice, Inc. and the Milwaukee Area Technical College (MATC) Announce Their Partnership in the Area of Procedural Medical Simulation
9. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
10. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
11. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
Post Your Comments:
(Date:11/30/2015)... ... , ... Global Stem Cells Group Chile CEO ... America and abroad for the first Iberoamerican Convention on Aesthetic Medicine, Cosmetology and ... will present and discuss new trends in anti-aging stem cell treatments, regenerative medicine ...
(Date:11/30/2015)... ... 30, 2015 , ... Global Stem Cells Group announced the opening of a new ... Arica and Iquique in northern Chile. The facilities are part of GSCG’s expansion efforts in ... and techniques in stem cell medicine to patients from around the world. , The clinics ...
(Date:11/30/2015)... 1, 2015 Partnership includes an ... for the u niversity , s ... treatment s cale - up ... Africa , where licensees based anywhere in the world will ... technology. --> Africa , where licensees based anywhere in the ...
(Date:11/30/2015)... 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the ... C.W. Wong to its Board of Directors to replace ... with a wealth of experience as co-founder of Resverlogix, with ... --> --> Dr. Wong remarked, ... of directors. Zenith,s long standing expertise in epigenetics and the ...
Breaking Biology Technology:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... Fingerprint Sensors - Technology and Patent Infringement Risk Analysis" ... --> --> Fingerprint sensors using capacitive ... The fingerprint sensor vendor Idex forecasts an increase of ... mobile devices and of the fingerprint sensor market between ...
(Date:11/19/2015)... VIEW, Calif. , Nov. 19, 2015  Based ... market, Frost & Sullivan recognizes BIO-key with the 2015 ... Leadership. Each year, Frost & Sullivan presents this award ... product line catering to the needs of the market ... the product line meets and expands on customer base ...
(Date:11/18/2015)... new scientific discoveries deepen our understanding of how cancer ... challenges in better using that knowledge to guide treatment ... children continue to survive pediatric cancer, that counseling may ... John M. Maris, M.D ., a pediatric oncologist ... --> John M. Maris, M.D ., ...
Breaking Biology News(10 mins):